Dunedin (NZ) biotech company Blis Technologies has opened a portal into a potential $200 million market by signing a deal with Auckland-based Asia Pacific Biotech Distributors (APBD) to take its antibacterial Throat Guard into China. [ + ]

Melbourne drug delivery systems developer Acrux has signed a major deal with global pharmaceutical group Eli Lilly and Company to commercialise its veterinary product line. [ + ]

A tri-state research collaboration is set to use sibling pairs to examine the genetic reasoning behind the most common form of eczema [ + ]

Two animal-virus hunters at CSIRO are exploring the potential of advanced genetic and proteomics technologies to make more accurate and rapid diagnoses of viral diseases and other microbial infections of livestock. [ + ]

Development-stage biotechnology company Virax Holdings (ASX: VHL) has raised $3.4 million in a capital raising aimed to progress its prostate cancer and HIV drug development programs. [ + ]

Brisbane small molecule drug development company Peplin Biotech (ASX: PEP) today announced the appointment of its new chief executive. [ + ]

More than half of Australia's carbon dioxide emissions come from power stations. Storing these harmful gases underground can drastically reduce the rate of emission build-up in our atmosphere.

University of Queensalnd historian Dr Sarah Ferber is redefining contemporary bioethics to include a historical dimension. And she's planning a book exploring topics such as medicine and social morality, human experimentation, women and reproductive medicine, genetic research and euthanasia.

Cancer researchers in Melbourne and Innsbruck hunting for new options to treat cancer have flushed two promising new therapeutic targets from the genetic thickets of the p53-mediated apoptosis pathway: Puma and Noxa. [ + ]

The University of Newcastle and the Hunter Medical Research Institute have linked up with international life sciences supply company Amersham BioSciences to establish a sophisticated analytical laboratory for research into personalised medicine. [ + ]

Diabetes luminary Prof Paul Zimmet has been honoured by his peers, receiving the Kellion Award for his contribution to the field. [ + ]

A nano-structured silicon device containing slow-release radiotherapy has successfully halted tumours in an animal study. [ + ]

Research into a promising new anti-diabetes compound derived from tree bark will receive a major funding boost under a heads of agreement deal brokered in Melbourne this week. [ + ]

Small molecule drug company Progen Industries (ASX:PGL, Nasdaq:PGLAF) has doubled its cash reserves in a share placement aimed to help the Brisbane biotech expand its product pipeline. [ + ]

It has been a week for collaborations at the Melbourne-based polyvalent nanotechnology development company, Starpharma (ASX:SPL). [ + ]